Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex
2009
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Complete Replication of Hepatitis C Virus in Cell Culture
2005 StandoutScienceNobel
Characterization of a canine homolog of hepatitis C virus
2011 StandoutNobel
A drug-controllable tag for visualizing newly synthesized proteins in cells and whole animals
2008 StandoutNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism
2009 StandoutNobel
Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions
2021 StandoutNobel
The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication
2009
Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target
2010
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Challenges and successes in developing new therapies for hepatitis C
2005 Nature
Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins
2014
Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro
2006
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
2004
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
2020 Standout
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Update on alisporivir in treatment of viral hepatitis C
2012
Completion of the entire hepatitis C virus life cycle in genetically humanized mice
2013 StandoutNatureNobel
Identification of Human Kinases Involved in Hepatitis C Virus Replication by Small Interference RNA Library Screening
2007
Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir
2007
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice
2005
Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics
2009
Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)
2011
A CRISPR toolbox to study virus–host interactions
2017
Identification of the Niemann-Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor
2012
Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents
2011
Characterization of resistance mutations against HCV ketoamide protease inhibitors
2008
Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy
2009
The role of resistance in HCV treatment
2012
What are the pros and cons of the use of host-targeted agents against hepatitis C?
2014
Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology
2007
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
2005 StandoutNature
A Major Determinant of Cyclophilin Dependence and Cyclosporine Susceptibility of Hepatitis C Virus Identified by a Genetic Approach
2010
Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication
2012
Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A
2010
The Serine Protease Domain of Hepatitis C Viral NS3 Activates RNA Helicase Activity by Promoting the Binding of RNA Substrate
2007
Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo
2011
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus
2010
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors
2010
Cyclophilin inhibitors in hepatitis C viral infection
2007
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
2011
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
2009 StandoutNatureNobel
DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
2010
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice
2010
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
2009
A Simple Enantioconvergent and Chemoenzymatic Synthesis of Optically Active α‐Substituted Amides
2011 StandoutNobel
Hepatitis C Virus NS5B and Host Cyclophilin A Share a Common Binding Site on NS5A
2012
Hepatitis C virus NS5A inhibitors and drug resistance mutations
2014
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
2007 StandoutNatureNobel
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A
2010
Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B
2007
Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
2020 StandoutNobel
Hepatitis C Virus Entry
2007 StandoutNobel
SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders
2007
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study
2006
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
A genetically humanized mouse model for hepatitis C virus infection
2011 StandoutNatureNobel
Domain 3 of NS5A Protein from the Hepatitis C Virus Has Intrinsic α-Helical Propensity and Is a Substrate of Cyclophilin A
2011
Inhibition of HCV Replication by Cyclophilin Antagonists Is Linked to Replication Fitness and Occurs by Inhibition of Membranous Web Formation
2014
Therapy of Hepatitis C: From Empiricism to Eradication
2006
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
TMEM41B Is a Pan-flavivirus Host Factor
2020 StandoutNobel
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
2006
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro†
2006
A Fluorogenic Aryl Fluorosulfate for Intraorganellar Transthyretin Imaging in Living Cells and in Caenorhabditis elegans
2015 StandoutNobel
Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro
2007
Inhibitors of the Tick-Borne, Hemorrhagic Fever-Associated Flaviviruses
2014
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens
2016 Nature
Expression of MicroRNA miR-122 Facilitates an Efficient Replication in Nonhepatic Cells upon Infection with Hepatitis C Virus
2012
Engineered Biosynthesis of β‐Alkyl Tryptophan Analogues
2018 StandoutNobel
Covalent Modifiers: An Orthogonal Approach to Drug Design
2009
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Suppression of Viral RNA Binding and the Assembly of Infectious Hepatitis C Virus Particles In Vitro by Cyclophilin Inhibitors
2012
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
A virocidal amphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro
2008
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Modeling hepatitis C virus infection using human induced pluripotent stem cells
2012 StandoutNobel
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
Development of an Intergenotypic Hepatitis C Virus (HCV) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS3 Protease Genes from HCV Genotypes 1 to 6
2010
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
2010
Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors
2008
Toward stereocontrolled, chemoenzymatic synthesis of unnatural peptides
2008
Regulation of apoptosis by the circadian clock through NF-κB signaling
2011 StandoutNobel
Syn-Selective Synthesis of β-Branched α-Amino Acids by Alkylation of Glycine-Derived Imines with Secondary Sulfonates
2015
Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System
2007
Review HCV Antiviral Resistance: The Impact of in vitro Studies on the Development of Antiviral Agents Targeting the Viral NS5B Polymerase
2005
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19
2020
Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells
2006 StandoutNobel
Development of a Cell-Based Hepatitis C Virus Infection Fluorescent Resonance Energy Transfer Assay for High-Throughput Antiviral Compound Screening
2009
Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro
2008
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle
2010 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA ReplicationIn Vitro
2009
Evaluation of Phosphatidylinositol-4-Kinase IIIα as a Hepatitis C Virus Drug Target
2012
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures
2010 StandoutNobel
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
2011
Synthetic Approaches and Pharmacological Activity of 1,3,4-Oxadiazoles: A Review of the Literature from 2000–2012
2012
Future Therapies for Hepatitis C
2006
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro
2005
Works of Kai Lin being referenced
Multiple Stress Signals Induce p73β Accumulation
2004
Anti-HCV drugs in the pipeline
2011
Development of novel antiviral therapies for hepatitis C virus
2010
In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
2005
Multiple cyclophilins involved in different cellular pathways mediate HCV replication
2009
HCV NS5A and IRF9 compete for CypA binding
2012
Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion
2011
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
2004
Curing a viral infection by targeting the host: The example of cyclophilin inhibitors
2013
Inhibitors of hepatitis C virus NS3·4A protease 2. Warhead SAR and optimization
2004
Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics
2007
Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance
2008
Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells
2004
137 VX-950: a tight-binding HCV protease inhibitor with a superior sustained inhibitory response in HCV replicon cells
2003
[608] NIM811, A CYCLOPHILIN INHIBITOR, AND NM107, AN HCV POLYMERASE INHIBITOR, SYNERGISTICALLY INHIBITS HCV REPLICATION AND SUPPRESSES THE EMERGENCE OF RESISTANCE IN VITRO
2007
NIM811, A Cyclophilin Inhibitor, and NM107, An HCV Polymerase Inhibitor, Synergistically Inhibits HCV Replication and Suppresses the Emergence of Resistance In Vitro
2007
NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon
2006
Mechanism of Resistance of Hepatitis C Virus Replicons to Structurally Distinct Cyclophilin Inhibitors
2010
VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells
2006
Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to Alisporivir
2012